Verastem Oncology (NASDAQ: VSTM) is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel anti-cancer medications. The company focuses on treating complex and difficult-to-treat cancers by targeting critical signaling pathways, such as RAF/MEK and KRAS pathways, with flagship combination therapies aimed at improving patient outcomes in areas like low-grade serous ovarian cancer and pancreatic cancer.